|
|
|
Volumn 15, Issue 4, 2002, Pages 307-
|
|
Novel and future strategies in the management of IBD
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTIBIOTIC AGENT;
BETA INTERFERON;
CERTOLIZUMAB PEGOL;
GLUCOCORTICOID;
INFLIXIMAB;
INTERLEUKIN 10;
INTERLEUKIN 12 ANTIBODY;
INTERLEUKIN 16;
INTERLEUKIN 1BETA;
INTERLEUKIN 6;
INTERLEUKIN 8;
MOLECULAR MARKER;
MONOCLONAL ANTIBODY;
PLACEBO;
STEROID;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
ALGORITHM;
ANTIINFLAMMATORY ACTIVITY;
CROHN DISEASE;
CYTOKINE RELEASE;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG SAFETY;
DRUG WITHDRAWAL;
EDITORIAL;
ENCEPHALOMYELITIS;
ENTERITIS;
HUMAN;
MAINTENANCE THERAPY;
OUTCOMES RESEARCH;
PATHOPHYSIOLOGY;
PROTEIN EXPRESSION;
REMISSION;
REPEATED DRUG DOSE;
RISK BENEFIT ANALYSIS;
SIGNAL TRANSDUCTION;
ULCERATIVE COLITIS;
UPREGULATION;
|
|
EID: 34548802052
PISSN: 11087471
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (1)
|
|
References (0)
|
